PCOS and Hyperprolactinemia: what do we know in 2019?
Clémence Delcour, Geoffroy Robin, Jacques Young...
https://pubmed.ncbi.nlm.nih.gov/31523136Actively Recruiting
Led by Mst.Sumyara Khatun · Updated on 2025-12-16
72
Participants Needed
1
Research Sites
25 weeks
Total Duration
M
Mst.Sumyara Khatun
Lead Sponsor
B
Bangladesh Medical University
Collaborating Sponsor
Researchers are studying women with polycystic ovary syndrome (PCOS) who are seeking to become pregnant. The study compares whether combining two drugs, cabergoline and letrozole, helps increase the rate of ovulation better than using letrozole alone. This randomized controlled trial involves participants diagnosed with PCOS according to the Rotterdam criteria and focuses on ovulation induction to improve fertility outcomes. Participants are randomly assigned to one of two groups. The experimental group takes cabergoline tablets twice on days 2 and 9 of their menstrual cycle plus letrozole tablets daily for five days starting on day 2. The comparison group takes only letrozole tablets daily for five days starting on day 2. Treatments continue for up to three menstrual cycles. Ovarian response is monitored using transvaginal ultrasound to check follicle growth on day 12 of each cycle. Participants will attend multiple visits each cycle for initial assessments, medication administration, ultrasound monitoring, and blood tests to confirm ovulation by measuring progesterone levels. Pregnancy testing and ultrasound for fetal heartbeat are done if menstruation is missed. The main outcome measured is ovulation rate within 21 days after each cycle, with additional monitoring of follicle size, ovulation confirmation, and pregnancy occurrence over 12 weeks.
CONDITIONS
Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 menstrual cycles (approximately 12 weeks)
Participants receive ovulation induction treatment with cabergoline plus letrozole or letrozole alone for up to 3 menstrual cycles. Treatment starts on day 2 of menstruation or withdrawal bleeding each cycle. Participants take medications and undergo monitoring of follicle growth and ovulation confirmation.
At least four visits per cycle: baseline assessment, ovulation induction, follicle monitoring on day 12, and serum progesterone measurement for ovulation confirmation; additional visits for pregnancy testing if period is missed
Total: 1 location
1
Bangladesh Medical University
Dhaka, Shahbag, Bangladesh, 1000
Actively Recruiting
M
Mst.Sumyara Khatun, MS
N
Nespatul Jannat, MBBS
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Clémence Delcour, Geoffroy Robin, Jacques Young...
https://pubmed.ncbi.nlm.nih.gov/31523136Shlomo Melmed, Felipe F Casanueva, Andrew R Hoffman...
https://pubmed.ncbi.nlm.nih.gov/21296991